BMO Analyst, Ian Somaiya, cut his PT on Intercept Pharmaceuticals (NASDAQ: ICPT) on slower NASH trial enrollment. Price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE